However, recent studies showed that BRAF and NRAS mutations can co-occur in some melanoma cells of BRAF-resistant patients, and their presence is associated with a heterogeneous and variable response to different types of inhibitors of MEK, ERK, PI3K, and AKT [31]. Here, NRAS is linked to melanoma.